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Abstract Cancer and cardiovascular disease (CVD) are two
major causes of mortality in older adults. With improved sur-
vival and outcomes from cancer and CVD, the role of the
geriatrician is evolving. Geriatricians provide key skills to
facilitate patient-centered and value-based care in the growing
older population of cancer patients (and survivors). Cancer
treatment in older adults is particularly injurious with respect
to complications stemming from cancer therapy and as well as
to CVD related to cancer therapy in the context of physiologic
aging. To best meet their natural potential as caregiving
leaders, geriatricians must hone skills and insights pertaining
to oncologic and cardiovascular care, insights that can inform
and enhance key management expertise. In this paper, we will
review common chemotherapy and radiation-induced cardio-
vascular complications, screening recommendations, and ad-
vance the concept of a geriatric, cardiology, and oncology
collaboration. We assert that geriatricians are well suited to a
leadership role in the care of older cardio-oncology patients
and in the education of primary care physicians and subspe-
cialists on geriatric principles.
Keywords Geriatric cardiology . Geriatric oncology .
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Introduction
Cancer and heart disease are the leading cause of death in
patients older than 60 years of age [1]. While cancer is the
number one cause of mortality in patients between 60 and
79 years, heart disease is most common in people aged 80
and older [1]. Therefore, the role of geriatricians in these spe-
cific subspecialties is of particular significance. Geriatric car-
diology and geriatric oncology have long been respective part-
ners because advances in cancer and cardiovascular (CV) care
have increased life expectancy. With the increasing need to
address CV consequences of chemotherapy and/or radiation
therapy, the field of Bcardio-oncology^ or Bonco-cardiology^
faces renewed interest. Because cancer and heart disease are
pathology related to the aging process, a close partnership
between geriatric cardiology and cardio-oncology is also nat-
ural, and geriatricians have an important opportunity to devel-
op as clinical leaders at this emerging crossroad. In many
cases, the goals of management are not solely focused on
survival but also on other markers such as quality of life,
functional status, and individual patient preferences.
We present a case study to demonstrate tensions within this
burgeoning discipline: a fully functional and active 69-year-
old Caucasian female with a history of chronic anemia, hyper-
tension, and dyslipidemia was admitted for hip fracture fol-
lowing a mechanical fall. During the evaluation of her fall, she
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was diagnosed with multiple myeloma as the underlying eti-
ology of her fracture. With daily intensive physical therapy,
she made gradual and steady improvement in her functional
status. At the oncology visit, she was considered to be Bhigh
risk^ based on genetic testing and was initiated on induction
therapy with four cycles of bortezomib, lenalidomide, and
low-dose dexamethasone. Subsequently, she was admitted
with new onset shortness of breath and leg swelling and found
to have new onset congestive heart failure (CHF) and exten-
sive right iliac vein thrombosis. Echocardiography showed a
left ventricular ejection fraction (LVEF) of 20–25 % despite a
normal pre-chemo echo. Cardiology was consulted. Left heart
catheterization showed non-obstructive coronary artery dis-
ease (CAD), and she was started on a cardiomyopathy regi-
men. Potential placement of an implantable cardioverter defi-
brillator (ICD) if her LVEF remained low after optimal med-
ical therapy was discussed.
The patient’s sequelae of CHF and venous thrombosis were
complications of bortezomib [2] and lenalidomide [3], respec-
tively. Although the development of cardiomyopathy might
have been unavoidable, how might we approach her case if
she were a frail vs functional 69-year-old? Given her age and
risk factors for CAD, should she have undergone a CV eval-
uation prior to the therapy initiation? This case is an example
of the current practice model whereby management of CV
complications is reactionary. Although the patient was man-
aged accordingly, her care could have been enhanced with
proactive involvement of cardiology during the evaluation
for chemotherapy. In geriatric patients, particularly those
who have limited functional status, complications from che-
motherapy and/or radiation may be insidious and present
themselves much later.
Excellent reviews on the CVeffects of chemotherapy and/
or radiation therapy [4••, 5••, 6–12] as well as malignancies
common to older adults and decision-making strategies [13,
14, 15••, 16, 17] have been published. Barac et al. have also
outlined a roadmap for taking cardio-oncology to the next
level in clinical care, research, education/training, and in es-
tablishing collaborative networks [18••]. In this review, we
aim to provide a basic foundation for understanding chemo-
therapy and/or radiation-induced CV complications, discuss a
framework for geriatric–cardiology–oncology (geri-cardio-
onc) collaborations, and advocate for a paradigm shift to en-
able geriatricians to lead the conversation both in advocating
for care and in educating other physicians about geriatric
principles.
Cardiotoxicity and Guideline-Based Screening
Cancer therapeutics including traditional chemotherapy,
targeted therapy, radiotherapy, and hormonal therapy all have
short- and long-term systemic effects, often involvingmultiple
organs. However, CV toxicities have been most concerning
and can result in irreversible CV damage or reversible cardiac
dysfunction. These adverse events may be related to direct
effects on myocytes or indirect effects on the CV system,
which in turn may increase the risk of CV disease [9]. Stuter
and Ewer [19] suggested a classification system for identify-
ing chemotherapies causing irreversible (type I cardiotoxicity,
associated with cell loss, anthracyclines and mitoxantrone)
and reversible cellular dysfunction (type II cardiotoxicity, dys-
function of mitochondria and protein structures, biologic
agents) [20]. Despite limitations of this classification sys-
tem (such as irreversible damage precipitated by a type II
agent in a patient with pre-existing CV disease), the con-
cept is foundational in deciding whether or not to proceed
with cancer therapy. A spectrum of chemotherapy and/or
radiation-induced CV complications exists: arrhythmias,
cardiomyopathy and left ventricular dysfunction (LVD),
valvular and pericardial disease, ischemic disease, as well
as vascular disease. However, LVD and cardiomyopathy
have received significant attention in recent years due to
their long-term implications.
A consensus definition for cardiotoxicity is still lacking.
The Cardiac Review and Evaluation Committee defines LV
dysfunction as B(1) a decrease in LVEF that was either global
or more severe in the septum, (2) symptoms of congestive
heart failure, (3) signs of CHF (S3 gallop, tachycardia, or
both), and (4) decline in LVEF of at least 5 % to less than
55 % with signs or symptoms of heart failure or a decline of
LVEF by at least 10 % to below 55 % without signs or
symptoms^ (of heart failure) [5••]. Other definitions include
a larger change in LVEF to less than 50 %. According to
recommendations by the American Society of Echocardiogra-
phy (ASE) and the European Association of CV Imaging
(EACVI) [21••], LVD may be defined as a decrease of greater
than 10 % to an LVEF <53 % by 2D echo or a decrease of
>15 % in 2D-derived global longitudinal strain (GLS) from
baseline echo. At baseline, LVD is characterized as 2D LVEF
<53 % with confirmation by cardiac MRI or 2D GLS that is
less than the lower limits of normal (which is vendor-depen-
dent). In addition to a decrease in LVEF and the symptomatic
vs asymptomatic nature, another dimension warranting inclu-
sion is reversibility: Breversible = improvement to within 5
percentage points of baseline; partially reversible = improve-
ment by 10 points but remaining within 5 percentage points of
baseline; irreversible = remaining within 10 percentage points
of the nadir; and indeterminate = re-evaluation not available^
[21••]. The timeframe for re-assessing reversibility varies de-
pending on the specific chemotherapeutic agent but can be
generalized based on recommendations summarized in
Table 1.
For many physicians and patients, acute or short-term ef-
fects of chemotherapy and/or radiation therapy tend to be at
the forefront of their concerns. However, potential late effects,
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which can present decades later, are often insidious. There-
fore, in certain populations, such as older adult survivors of
cancer, vigilance, and awareness may assist in earlier
diagnosis.
Cardiomyopathy and Vascular Effects Major groups of
chemotherapeutic drugs that can cause cardiotoxicity, the time
to presentation, their proposed mechanisms, and strategies for
mitigation are outlined in Table 2. Of these agents,
anthracyclines are the most widely studied and represent the
most effective class of drugs for hematologic and solid organ
malignancies [22, 23] such as sarcomas, lymphomas, leuke-
mias, and breast cancer. However, their use is limited by po-
tential LVD and heart failure. Anthracycline-induced
cardiotoxic effects are dose dependent, and those who develop
late cardiotoxicity have a high mortality [24]. Risk factors
include cumulative dose, bolus administration, high single
dose, prior radiotherapy, simultaneous use of other cardiotoxic
agents, female gender, bimodal age distribution (very young
and very old), existing CV disease, elevation of cardiac bio-
marker during and after cancer treatment, as well as time since
completion of cancer therapy. Nonspecific electrocardio-
graphic changes such as ST-T wave abnormalities have been
observed in 20 to 30 % of patients undergoing therapy with
anthracyclines [25] and may herald early manifestations of
anthracycline cardiotoxicity but are often not acted upon due
to lack of other clinical manifestations. Important in the deter-
mination of risk is the predisposition to having cardiotoxic
effects. This predisposition is thought to be multifactorial
and reflects a combination of genetic, environmental, and
existing medical comorbid conditions [26]. Much work in
the area of -omics (genomic, proteomic, metabolomics) and
risk modeling is needed to provide personalized risk stratifi-
cation. Further, significant vigilance is needed during and after
therapy, particularly in the older population who often have a
high burden of underlying CVD. Although observational and
clinical data exist to support increases in risk of anthracycline-
induced cardiotoxicity with age (>65 years for anthracyclines
[27••], >80 years for trastuzumab [28]), it is less clear whether
there is an association of cardiotoxicity with age for newer
therapies, but the latter may be reflective of an under-
representation of adults older than 65 years and especially
those >80 years, in clinical trials [29].
A second class of frequently used cardiotoxic agents are
targeted therapies including monoclonal antibody-based tyro-
sine kinases (bevacizumab, trastuzumab) and small molecule
tyrosine kinase inhibitors (sorafenib, sunitinib, lapatinib)
[30–32]. Targeted therapies are often used in breast, lung,
colorectal, and renal carcinomas. Hypertension is a common
adverse event whose mechanism is not well understood but
has been attributed to the inhibition of vascular endothelial
growth factor (VEGF) [33, 34], which can result in decreased
microvascular density. Thromboembolic events are infrequent
but have also been implicated with anti-VEGF agents [7]. LV
dysfunction also occurs but less common. Of the targeted
agents, trastuzumab has been found to have a higher than
expected incidence of CHF and LVD [35, 36] and can pose
higher risk of LVD in those previously treated with
Table 1 General algorithms for screening and monitoring of
chemoradiation-induced cardiovascular complications [21••, 27••, 59••]
Chemotherapeutics—anthracycline-based therapy (type I injury)b [5••]
• Baseline cardiac evaluation and echocardiogram
• Troponin evaluation at each cycle
Troponin positive
▪ Enalapril × 1 year; echo at completion of chemo, then at 3–6–9–
12 months post-chemo in the first year
▪ Echo every 6 months after the first year × 5 years
Troponin negative
▪ Echo at 12 months, then echo every year thereafter
• No troponin evaluation during chemotherapy
▪ Echo at end of chemotherapy and at 3–6-9–12 months post-
chemo in the first year, then annually
▪ If LVDa develops, then treatment with ACEI + BB + clinical
evaluation and follow-up
Chemotherapeutics—trastuzumab therapy (type II injury)b [5••]
• LVEF ≥50 %→ initiate treatment
• LVEF <40 %→ hold treatment and repeat echo in 3 weeks
• LVEF between 40 and 50 %
• LVEF >10 % points below baseline
▪ Hold treatment, repeat echo in 3 weeks
▪ If repeat LVEF <40 %, stop treatment
▪ If repeat LVEF ≥45 % or remains 40–50 %, then resume
treatment
LVEF <10 % points below baseline→ continue treatment
Radiotherapy [59••]
• Baseline pre-radiation echocardiogram
• Yearly focused clinical exam searching for signs and symptoms of
cardiovascular disease, screen for modifiable risk factors and treat
• Diagnostic evaluation if signs/symptoms of cardiovascular disease
• Asymptomatic
Screening echo at 5 years for high risk patients and 10 years for
others
Functional non-invasive stress test for detection of ischemic heart
disease 5 to 10 years after exposure in high risk patients
Reassess every 5 years for need of echo and/or stress testing
a Consensus definition for left ventricular dysfunction (LVD) is lacking
but is defined as a decrease of greater than 10% to an LVEF <53% by 2D
echo or a decrease of >15 % in 2D-derived global longitudinal strain
(GLS) from baseline echo [21••]. At baseline, LVD is characterized as
2D LVEF <53 % with confirmation by cardiac MRI or 2D GLS less
than the lower limits of normal. Repeat echo should be performed 2–
3 weeks after the baseline study showing a decrease in LVEF
b The American Society of Echocardiography and the European Associ-
ation of Cardiovascular Imaging recommend cardiology consultation in
both type I and type II injury when LVEF ≤53 % and suggest increased
sensitivity and specificity for detection of subclinical disease when LVEF
is used in concert with GLS measurements during the initiation and mon-
itoring of cardiotoxicity [21••]
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anthracyclines or those undergoing concurrent therapy with
anthracyclines.
Ischemic Heart Disease Cardiac ischemia is a known com-
plication of many chemotherapeutic drugs but is an unusual
occurrence and more often associated with cytotoxic and
targeted therapy. Progression of or acceleration of ischemic
disease is more common with radiation therapy. Agents such
as bleomycin, etoposide, cisplatin [37–40], 5-fluorouracil
(FU) [41–44], as well as newer anti-VEGF agents [45, 46]
have been implicated in the development of myocardial ische-
mia including myocardial infarction. The pathogenesis of 5-
FU-mediated cardiac ischemia appears to involve
endothelium-independent vasoconstriction and coronary va-
sospasm [47]. Although coronary vasospasm appears to be
central in the development of myocardial ischemia from 5-
FU, arterial thromboembolism may also be implicated [45,
46]. A post hoc analysis by Scappaticci et al. showed a higher
risk of arterial thromboembolism in patients treated with con-
ventional chemotherapy and bevacizumab as compared to pa-
tients treated with chemotherapy alone (3.8 vs 1.7 % (95 %
CI=0.7 to 3.7 %) [48]. As newer targeted therapies become
more widely used, those with anti-VEGF or anti-angiogenesis
properties require close attention, particularly when used in
patients with risk factors for CAD or known CAD. For older
men with prostate cancer undergoing treatment with androgen
deprivation therapy (ADT), the verdict remains inconclusive
as data on the association of ADT with CVD have been in-
consistent. Although there are reports of an increased risk of
heart disease including CAD, acute ischemia, and sudden car-
diac death [49–54], there are also other studies showing no
increased risk of CV morbidity and mortality [55–57].
Radiation-Induced Injury A large body of literature sup-
ports CV injury following chest radiotherapy [5••]. However,
the patient population that is most affected by radiotherapy-
induced CV injury is adult cancer survivors treated with ra-
diotherapy at a relatively young age and therefore has a longer
time horizon to develop late cardiac effects. These typically
include those with Hodgkin’s lymphoma, early stage breast
cancer, lung, and esophageal cancer. Mediastinal radiotherapy
may lead to disease of the coronaries, valves, myocardium,
pericardium, and conduction system [58]. Risk factors for
radiation-induced CV injury include radiation dose >30–
35 Gy or dose per fraction >2 Gy, anterior or left chest irradi-
ation, large volume of cardiac exposure, younger age at expo-
sure, longer time since exposure, combination therapy with
cytotoxic chemotherapy, hormonal therapy, anthracyclines,
or trastuzumab, known CV disease, as well as risk factors
for cardiac disease (diabetes, hypertension, dyslipidemia, obe-
sity, smoking) [59••]. For those with Hodgkin’s lymphoma,
the time horizon for risk of fatal CVevents is 2–7 years post-
radiotherapy, while for those with left-sided breast cancer, the
range is 1.0–2.2 years [5••].
Device Therapy Some patients face acute LVD during treat-
ment, while others may present with LVD as a late effect. If
LVD remains ≤35 % after treatment with optimal cardiomy-
opathy medications and if there is greater than one year of
expected survival, patients are eligible for ICD therapy as
primary prevention of sudden cardiac death [60]. Although
studies have shown improved survival in patients with ICD
compared to optimal medical therapy alone [61, 62] and there
is improved quality of life in those who have not experienced
shock therapy [63, 64], these data are not specific to those who
have LVD secondary to chemotherapeutics. Further, chemo-
therapy and/or radiation therapy may cause conduction dis-
ease or progression of underlying conduction disease,
resulting in the need for pacemaker therapy. In discussing
device therapy, particularly in the older cancer patient, it is
important to stress that ICD therapy can be easily deactivated
at any time to prevent shocks (i.e., when shock therapy be-
comes dyssynchronous with the patient’s goals of care). De-
activation of pacemakers on the other hand may rarely result
in immediate death for those who become pacemaker depen-
dent. Importantly, pacemaker deactivation can induce a rapid
progression of symptoms such as fatigue, dizziness, or short-
ness of breath [65]. In deciding which patients are appropriate
and may benefit from advanced device therapy, one must con-
sider the patient’s overall cancer prognosis, social support risk
of complications such as bleeding and infection, as well as the
patient’s preferences.
Guideline-Based Screening and Monitoring Surveillance
andmonitoring consensus statements by the European Society
for Medical Oncology (ESMO) [5••] and imaging societies
[21••, 59••] have been published. The National Comprehen-
sive Cancer Network (NCCN) [66] and Society for Geriatric
Oncology [27••] (SIOG) have also released publications on
the care of the older cancer patient—both of which cover CV
complications and management. NCCN also provides age-
specific guidelines on their website with recommendations
outlining treatment of anthracycline-related cardiotoxicity. Ta-
ble 1 summarizes general algorithms for monitoring and man-
agement. Publications by SIOG and NCCN [27••, 66] address
the older population specifically, while the joint scientific
statement by the ASE and the EACVI [21••] address monitor-
ing in adults of all ages. The statement by Lancellotti et al.
provides recommendations for adults treated with radiothera-
py [59••]. Despite recent scientific statements, a paucity of
data exists to help form strong evidence-based recommenda-
tions in the cardio-oncologic care of the older, medically com-
plex patient. Dale et al. in their article on the interface of
cancer and aging research [67] outlined selected clinical trials
which enrolled older patients with cancer (12 in total—two
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trials in breast cancer, two lung cancer, two colorectal cancer,
two acute myeloid leukemia, three prostate cancer, and two
ovarian cancer). They noted several themes: (1) few clinical
trials are designed specifically for older patients with cancer,
(2) the actual proportion of older patients in clinical trials is
not reflective of that in the general population, and (3) mea-
sures of functional/physiologic age are not routinely included
in the study design. Often, older patients with known CV
disease are also excluded. Further, it is difficult to know
whether the CV complications observed in these trials reflect
the true incidence and prevalence in the general older adult
population as many older patients have subclinical cardiac
disease that may manifest during the course of cancer therapy
or be exacerbated by the treatment.
Chronologic vs Physiologic Age and the BFitness^ of an
Older Patient with CV Disease to Undergo Cancer
Therapy
Chronologic age by itself is a poor predictor of outcomes
including life expectancy, functional reserves, and risk of
complications [68]. Risk factors for chemotherapy associated
adverse events involve a combination of underlying comor-
bidities (renal insufficiency, lung disease, hearing or visual
loss, gastrointestinal disease, neuropathy, osteoporosis, diabe-
tes, anemia, known CHF), geriatric syndromes (functional
dependence, decline in mobility, falls, dementia, delirium, de-
pression, polypharmacy, nutritional deficiency), and socioeco-
nomic factors (low income, lack of caregiver or transportation,
poor living conditions, or lack of drug coverage) [66, 67, 69,
70]. Both oncologists and cardiologists are often called upon
to assess an older patient’s Bfitness^ to undergo cancer thera-
py, particularly if the patient has known ischemic heart disease
or LVD. Predictive models such as Chemotherapy Risk As-
sessment Scale for High-Age Patients (CRASH) [71] or Can-
cer and Aging Research Group (CARG) [70] are available for
assessing chemotherapy risk and take into account the geriat-
ric assessment in predicting toxicity. The Karnosky perfor-
mance status, which is based on functional impairment, can
also be used to predict risk of chemotoxicity. However, it has
been shown to be less predictive than CARG, which takes into
account additional factors such as tumor and treatment vari-
ables, laboratory values, and geriatric assessment questions
[70]. These models and scores are more likely familiar to
oncologists and some geriatricians but are likely less familiar
to cardiologists or cardio-oncologists. However, the shared
traits among these scores include the ability to walk a block,
falls, and gait speed—all reflecting cardiac health.
Of the statements reviewed, those issued by ESMO [5••]
are most explicit regarding a baseline, pre-chemotherapy eval-
uation. Note that level I–III reflects the strength of recommen-
da t ion ( I— the r e i s genera l ag reement tha t the
recommendation is useful and effective, II—there is diver-
gence in opinion whereby IIa indicates that the weight of
evidence/opinion is in favor of usefulness and IIb indicates
that the usefulness is less well established, III—there is gen-
eral agreement that the recommendation is not effective and in
some cases harmful), while letters A–C reflect the level of
evidence (A—data derived from multiple randomized trials,
B—data derived from single randomized or nonrandomized
studies, C—consensus expert opinions). The recommenda-
tions for a baseline assessment include (1) assessment of CV
risks including CAD and hypertension (level IA) based on
prior cumulative doses of anthracyclines (level IA: doxorubin
>500 mg/m2, liposomal doxorubicin >900 mg/m2; epirubicin
>720 mg/m2; mitoxantrone >120 mg/m2, idarubicin >90 mg/
m2); (2) LVEF assessment (level IA, if echocardiogram is
performed, diastolic measurements and LV end-diastolic di-
ameter should be noted); (3) 12-lead electrocardiogram (level
IB); (4) biomarkers including troponin, brain natriuretic pep-
tides, and neutrophil glucosaminidase-associated lipocalin for
renal injury (level IIIB); (5) treatment optimization of existing
cardiomyopathies and anti-ischemic regimen including revas-
cularization if clinically appropriate (level IA); and (6) mini-
mization of cardiotoxicity through the use of liposome-
encapsulated doxorubin and cardioprotective agents such as
dexrazoxane, beta blockers, ACE inhibitors, and aldosterone
antagonists (level IIIB). No recommendation exists for routine
performance of stress testing in the absence of ischemic symp-
toms or findings prior to chemotherapy.
Geri-Cardio-Onc Collaboration and a Paradigm
Shift
Because those 65 and older are more likely to have multiple
and complex medical diagnoses, having geriatricians assume
leadership in this conversation helps to avoid the Bsliding
door^ phenomenon [72]. In practices or institutions without
geriatricians, having primary care physicians who are well
versed in geriatric principles take the leading role can be also
be effective. The Bsliding door^ concept was coined by Albini
et al. and refers to the probability of a patient having diverse
outcomes based on first subspecialty encounter, such as
whether the patient was first seen by a cardiologist or an on-
cologist (Fig. 1). Once diagnosed with cancer, the patient’s
care is shifted to the oncologist for primary management; sim-
ilarly, if CV complications arise such as LVD, primary man-
agement is then shared between cardiology and oncology.
We would like to advocate for a collaborative patient-
centered paradigm (Fig. 2) whereby there is greater dialogue
throughout the course of care among three disciplines: geriat-
rics, oncology, and cardiology. This paradigm shift brings to
the forefront a prior concept whereby the geriatrician serves as
the patient’s primary advocate. Subspecialty expertise is
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sought, but the ultimate decision to proceed with subspecialty
recommendations and subsequent screening and follow-up
will rest with the geriatrician.
Although subspecialists are qualified to facilitate goals of
care (GOC) discussions and assess the patient’s Bfitness^ to
undergo chemotherapy and radiation treatment, geriatricians
are better positioned to lead the conversation and address
these issues from a holistic approach rather than an organ or
disease-specific viewpoint. Detailed GOC discussions, which
may include explanation of the possible mechanisms of death,
are delicate and sometimes daunting matters. Often, complex
issues regarding GOC are not discussed early enough or at all
until a sudden catastrophic event or diagnosis occurs. Recent
work by Narang et al. reported increased implementation of
durable power of attorney assignment (DPOA) by cancer pa-
tients between 2010 and 2012, but this was not associatedwith
end-of-life or GOC discussions [73]. Although there are lim-
itations associated with proxy-reported research methodology,
these findings support a communication gap between patient,
surrogates, and clinicians [74].
Having advance directives in place is a starting point but is
often insufficient when dealing with older adult patients with
multi-comorbidities [75, 76]. Living wills often vary in detail,
whereas DPOAs are not always capable or do not have prior
knowledge of the patient’s preferences. GOC discussions re-
quire constant ongoing negotiations, particularly in cases of pa-
tients with cancer and heart disease whereby treatment of one
carries significant complications for other comorbidities. Within
the GOC discussion, dialogue on outcomes following cardiac
arrest and cardiopulmonary resuscitation (CPR) merits specific
attention. Although recent work by Chan et al. [77••] concluded
that 60 % of adults age 65 years or older were alive at one year
following in-hospital cardiac arrest and that the 3-year survival
rate is similar to patients with heart failure, others argue that the
relevant point of discussion should have centered on the finding
that among older survivors of in-hospital cardiac arrest, less than
10 % are alive at one year [78•] while the rate of survival to
discharge is 17 % across all ages [79•]. Glavan et al. [80•] have
also pointed out that the majority of those of who receive in-
hospital CPR die before discharge and that while CPR resulted
in 27 % of patients achieving return of spontaneous circulation,
the same percentage of patients did not survive to discharge [81].
In older patients with out-of-hospital cardiac arrest (OHCA),
there is a 25% survival to discharge from the intensive care unit,
22 % survival to hospital discharge, 20 % at 6 months, 19 % at
1 year, and 8 % at 5 year follow-up [82]. More recent data
indicate that advanced age (>70 years) is an independent predic-
tor of mortality in OHCA, albeit there was a small subset of
those >90 years who had a survival rate of >10 % [83].
Glavan et al. [80•] have suggested that CPR decisions be
based Bon the patient being informed about both the likelihood
of outcomes that are acceptable as well as the likelihood of
Fig. 1 The Bsliding doors^ concept—an example of diverse outcomes
based on first diagnosis [72]. The oncologist approaches the patient from
a cancer perspective and proceeds with therapy accepting the risk of later
cardiomyopathy diagnosis, while the cardiologist identifies the ischemic
heart disease, proceeds with appropriate therapy, and later finds cancer
from symptomatic bleeding secondary to anti-platelet therapy. From
Albini et al. [72], by permission of Oxford University Press
Fig. 2 A triad approach for geriatric–cardiology–oncologic care. In this
framework, the geriatrician (or primary physician well versed in geriatric
principles) takes the leading role by ensuring that treatment options are
discussed and presented in the context of the patient’s goals of care.
Further, the geriatrician facilitates care by bringing to the forefront
findings from the geriatric assessment and psychosocial dimensions that
may affect treatment recommendations. Frequency of follow-up studies
and monitoring of cardiovascular symptoms would rest with the geriatri-
cian and co-managed with the assistance of both cardiology and oncology
as needed
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outcomes that would not be acceptable.^ This suggestion may
provemore crucial in older adults with cancer and heart disease.
Having at minimum, an annual appointment dedicated solely to
the discussion of GOC with further re-negotiation each time a
major transition in the treatment plan occurs would be especial-
ly helpful. If possible, these discussions should be detailed in
progress notes and be made available to the entire medical
team. While the treatment of cancer may not result in death,
treatment complications may result in progression of heart dis-
ease, which may significantly alter the quality of life. Few
patients consider the potential for a decrease in quality of life
during the recovery period and many do not consider the unin-
tended consequences of treatment when deciding on treatment
options.
In the era of accountable care with medical homes, it is
assumed that there is a sense of greater intimacy in the pa-
tient–primary physician relationship and awareness of psycho-
social circumstances by the primary physician [85]—in this
case, a geriatrician, whose experience and expertise in commu-
nicating with the older adult population may have immeasur-
able effects on patient outcomes and treatment preferences.
Geriatricians are well-trained to manage patients with multiple
chronic conditions in a systematic, routine, and patient-centered
manner [84••]. Tools such as the comprehensive geriatric as-
sessment [68], life expectancy scoring [69], and frailty assess-
ment are common knowledge to the geriatrician. Cardiologists
and oncologists may be less familiar with and often have lim-
ited to no training in routinely performing geriatric assessments
and systematically evaluating for frailty. In addition, geriatri-
cians can help cardiologists and oncologists improve the quality
of care by proactively having GOC discussions with the patient
and his/her DPOA and communicating the impact of dementia,
depression, issues of nutritional deficiency, polypharmacy, as
well as socioeconomic factors (low income, lack of caregiver or
transportation, poor living conditions, etc.) [16, 17]. These is-
sues often affect treatment options.
Although we have focused on geriatricians assuming a lead-
ing role, we recognize that there are unlikely sufficient geriatri-
cians to provide the level of care that we propose. At the heart of
this paper is also the calling for geriatricians to educate physi-
cians who assume the role of the primary physician as well as
subspecialists who may care for older patients. At very few
academic institutions with Centers of Excellence, there may be
cardiologists or oncologists who specialize in geriatric cardiolo-
gy, geriatric oncology, or cardio-oncology. These experts may
have additional insight or background in geriatrics to conduct a
geriatric assessment and take into account issues specific to the
older patient. However, at institutions lacking these hybrid prac-
tices or Centers of Excellence, education of primary physicians
and other subspecialists by geriatricians can further facilitate
GOC discussions, improve the overall care, and ensure that
therapeutic options chosen and supportive care provided are
synchronous with the older patient’s preferences and values.
Conclusion
With advances in cancer and CV treatment, survival will im-
prove and life expectancy will be extended. Not only will the
initial diagnosis and treatment need attention, but physicians
will also be faced with treating unintended consequences of
these therapies. CV complications from cancer therapy, high
burden of underlying CV disease, and age-related changes in
physiology and metabolism represent the crossroads of geri-
atric cardiology and cardio-oncology. There is a paucity of
data available for evidence-based recommendations in the
cardio-oncologic care of older adult patients with cancer, but
recent consensus statements for general management have
been published to summarize available data and guide clinical
care. Multiple professional organizations, research collabora-
tions, and specialized centers have formed groups to address
issues relating to cardio-oncologic care. Within the geri-
cardio-onc collaborative framework, the geriatrician is well
positioned to take an active leadership role in advocating for
the patient, assisting with decision-making, and facilitating
screening and long-term monitoring of CV complications.
Further, education of primary physicians and subspecialists
by geriatricians about geriatric principles may prove helpful
in improving the overall quality of care in older adults.
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